Ongoing Clinical Trials for Coronary Artery Dissection
Currently, there is 1 ongoing clinical trial investigating treatment options for coronary artery dissection, specifically focusing on spontaneous coronary artery dissection (SCAD). This trial is examining the effectiveness of beta-blockers and antiplatelet medications in managing this condition. The study is being conducted in Spain and aims to provide valuable insights into better treatment approaches for patients affected by this heart condition.
Clinical trial locations
Study on the Effects of Metoprolol, Prasugrel, and Carbasalate Calcium in Patients with Spontaneous Coronary Artery Dissection
This clinical trial is investigating how certain medications can help patients who have experienced spontaneous coronary artery dissection. SCAD occurs when a tear forms in one of the blood vessels that supply the heart, which can lead to reduced blood flow and potentially serious complications like heart attacks. The condition is more commonly seen in women, particularly those who are pregnant or have recently given birth.
Main focus: The study aims to evaluate the effectiveness and safety of two types of medications in managing SCAD. The first type is beta-blockers, which help slow down the heart rate and reduce blood pressure, thereby decreasing stress on the heart. The second type is antiplatelet agents, which prevent blood clots by stopping platelets from sticking together. Participants will be randomly assigned to receive either the active medication or a placebo and will be monitored for up to 12 months.
Investigational drugs: The trial is testing several medications including:
- Beta-blockers: Metoprolol, Propranolol, Atenolol, Carvedilol, and Bisoprolol. These medications work by blocking the effects of adrenaline, which helps the heart beat more regularly and reduces its workload.
- Antiplatelet agents: Carbasalate Calcium, Prasugrel, Clopidogrel, and Ticagrelor. These drugs help prevent blood clots by keeping platelets from clumping together, which maintains smooth blood flow through the arteries.
Who can participate: The trial is looking for patients between 18 and 64 years old who have been admitted to the hospital for acute coronary syndrome or heart-related chest pain and have had SCAD confirmed by coronary angiography. Both men and women can participate. Participants must provide written informed consent, meaning they agree to join the study after being fully informed about what it involves.
Who cannot participate: The trial excludes several groups of patients, including those who have recently had a heart attack or stroke, individuals with severe heart failure or uncontrolled high blood pressure, and people with severe liver or kidney disease. Pregnant or breastfeeding women cannot participate, nor can individuals with known allergies to the medications being tested. People currently in another clinical trial or those with a history of drug or alcohol abuse are also excluded.
What happens during the trial: After joining the study and providing consent, participants will receive their assigned medications orally. Throughout the trial, researchers will monitor participants’ health closely, checking for major health events such as heart attacks, strokes, need for additional heart procedures, or hospital admissions. The study will also carefully track any bleeding events to assess the safety of the treatment. The trial is expected to conclude by February 28, 2026, at which point all results will be analyzed to determine how well the treatment strategy works.
Summary
Currently, research into coronary artery dissection is focused on spontaneous coronary artery dissection, with one active clinical trial underway in Spain. This trial represents an important effort to understand whether commonly used heart medications can help manage this condition more effectively. The study is examining both beta-blockers and antiplatelet agents, which are already well-established in treating other cardiovascular conditions. By investigating these medications in SCAD patients, researchers hope to develop evidence-based treatment guidelines for this relatively uncommon but serious heart condition. The focus on younger adults (18-64 years) reflects the typical age range of SCAD patients, particularly women of childbearing age who are disproportionately affected by this condition.
